Brief: Polypid Announces Recommendation By Data Safety Monitoring Board To Conclude Enrollment Of Phase 3 Shield I Trial Of D-Plex100
23/05/2022 12:49
May 23 (Reuters) - PolyPid Ltd PYPD.O :
* POLYPID ANNOUNCES RECOMMENDATION BY DATA SAFETY MONITORING BOARD TO
CONCLUDE
ENROLLMENT OF PHASE 3 SHIELD I TRIAL OF D-PLEX₁₀₀ AT THE MINIMUM NUMBER OF
PATIENTS TARGETED FOLLOWING UNBLINDED INTERIM EFFICACY ANALYSIS
* POLYPID LTD- ENROLLMENT OF 950 PATIENTS, MINIMUM NUMBER OF PATIENTS
TARGETED FOR
SHIELD I STUDY, EXPECTED WITHIN DAYS
* POLYPID LTD- TOP-LINE RESULTS EXPECTED BY END OF Q3 2022; POTENTIAL NDA
AND MAA
SUBMISSIONS TARGETED FOR H1 2023
Source text for Eikon: ID:nGNX4yYD5y
Further company coverage: PYPD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Polypid
See all newsPolyPid Ltd reports results for the quarter ended June 30 - Earnings Summary
PolyPid Ltd expected to post a loss of 38 cents a share - Earnings Preview
Brief: Polypid Announces FDA Acceptance Of NDA With Priority Review For D-Plex₁₀₀
PolyPid, Azurity sign surgical site infection drug deal
Brief: Polypid Initiates D-Plex₁₀₀ NDA Submission To The FDA